{
  "meta": {
    "title": "Thyroid_Parathyroid_Disorders_Part-1",
    "url": "https://brainandscalpel.vercel.app/thyroid-parathyroid-disorders-part-1-26507b56.html",
    "scrapedAt": "2025-11-29T18:24:48.438Z"
  },
  "questions": [
    {
      "id": 53981,
      "choices": [
        {
          "id": 215393,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Propylthiouracil</span></span></span></p>"
        },
        {
          "id": 215394,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Methimazole</span></span></span></p>"
        },
        {
          "id": 215395,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Radioactive Iodine Ablation</span></span></span></p>"
        },
        {
          "id": 215396,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Thyroidectomy</span></span></span></p>"
        }
      ],
      "text": "<p><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following should be avoided in children with Graves disease?</span></span></p>",
      "unique_key": "Q8553849",
      "question_audio": null,
      "question_video": null,
      "map_id": 25575,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Ans. A) Propylthiouracil</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Graves&rsquo; disease in children is usually managed initially with methimazole or carbimazole. Surgery or radioiodine may be indicated for severe or relapsing disease. Propylthiouracil is avoided in view of risk of hepatitis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option B. Methimazole:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> Preferred treatment in children with Graves disease. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option C. Radioactive Iodine Ablation:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> Usually reserved for refractory/severe Graves disease in children. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option D. Thyroidectomy:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> Usually reserved for refractory/severe Graves disease in children. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Propylthiouracil should be avoided in children with Graves&#39; disease due to the risk of hepatitis.</span></span></p>",
      "correct_choice_id": 215393,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53991,
      "choices": [
        {
          "id": 215433,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Observation and repeat USG in 6 months </span></span></span></p>"
        },
        {
          "id": 215434,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Fine needle aspiration biopsy (FNA) </span></span></span></p>"
        },
        {
          "id": 215435,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Radioiodine scanning </span></span></span></p>"
        },
        {
          "id": 215436,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Thyroid lobectomy</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">A 35-year-old woman presents with a palpable thyroid nodule and has normal TSH levels. USG reveals a hypoechoic solid nodule with microcalcifications. Which of the following is the most appropriate next step in management?</span></span></span></p>",
      "unique_key": "Q9929429",
      "question_audio": null,
      "question_video": null,
      "map_id": 25585,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Ans. B) Fine needle aspiration biopsy (FNA)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">TFT is usually normal in solitary nodules (and even in thyroid cancer). The presence of a hypoechoic solid nodule with microcalcifications on ultrasound raises suspicion for malignancy. FNA is the gold standard for evaluating thyroid nodules and is necessary to rule out cancer in this case.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">High risk features in USG:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> Solid, Hypoechoic, Tall than wide, lobulated/irregular, extra-thyroidal extension, peripheral/rim or punctate/micro calcifications.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option A. Observation and repeat USG in 6 months:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> This approach is suitable for smaller or less suspicious nodules but not for those with high-risk features like microcalcifications. Delayed diagnosis could lead to potential complications if the nodule is malignant.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option C. Radioiodine scanning:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> Useful only if hyperthyroid on TFTs. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option D. Thyroid lobectomy:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> Surgery is usually reserved for confirmed malignancy or large symptomatic nodules. FNA is required for diagnosis before considering surgery.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Papillary thyroid cancer generally has a good prognosis, and its presence is not associated with a poor prognosis compared to other types of thyroid cancer.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/17/screenshot-2024-08-17-142646_s0moNWZ.jpg\" style=\"height:815px; width:876px\" /></span></span></p>\r\n\r\n<p>&nbsp;</p>",
      "correct_choice_id": 215434,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53993,
      "choices": [
        {
          "id": 215441,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">BRAF mutation is the most common genetic alteration </span></span></span></p>"
        },
        {
          "id": 215442,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Lymph node micrometastases indicates poor prognosis. </span></span></span></p>"
        },
        {
          "id": 215443,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">It has a propensity to spread via the lymphatic system. </span></span></span></p>"
        },
        {
          "id": 215444,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">PTC is present in up to 25% of thyroid glands at autopsy</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">A 30-year-old man is diagnosed with papillary thyroid carcinoma (PTC). Which of the following statements is not true? </span></span></span></p>",
      "unique_key": "Q6925417",
      "question_audio": null,
      "question_video": null,
      "map_id": 25587,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Ans. B) Lymph node micrometastases indicates poor prognosis.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">PTC usually spreads primarily via lymphatic system. Lymph node involvement is prognostic but micro metastases (&lt; 2 mm) does not alter prognosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option A. BRAF mutation is the most common genetic alteration:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> True. a. BRAF V600E mutations reduce uptake of RAI and increase risk of recurrence (but effect on overall outcomes in unclear).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option C. It has a propensity to spread via the lymphatic system:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> This is true. PTC has a tendency to spread to the lymph nodes in the neck.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option D. PTC is present in up to 25% of thyroid glands at autopsy:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> This is also true. Many people have small, microscopic PTCs that never cause any problems. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Summary if important thyroid cancers: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">PTC:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> Most common type of thyroid cancer (80-85% of differentiated thyroid cancers)</span></span></span>\r\n\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Genetics: RET/PTC rearrangements (20-40%), <em>BRAF V600E mutation (most common),</em> RAS mutations (20-30%).</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<ol style=\"list-style-type:lower-alpha; margin-left:80px\">\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">BRAF V600E mutations reduce uptake of RAI and increase risk of recurrence (but effect on overall outcomes in unclear).</span></span></span></li>\r\n</ol>\r\n\r\n<ul style=\"list-style-type:circle; margin-left:40px\">\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Microscopic PTC is found in </span><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Cambria Math&quot;,serif\">&sim;</span></span><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">25% of autopsy thyroids (clinically insignificant).</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Characteristic cytological features: Orphan Annie eye appearance with Nuclear grooves and Prominent nucleoli.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Tall cell, columnar cell, hobnail, poorly differentiated &ndash; aggressive variants.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Can be multifocal &amp; invade locally within the thyroid gland/ adjacent structures.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Usually Spreads primarily via lymphatic system.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Slow growth can lead to a significant burden of pulmonary metastases with few symptoms.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Lymph node involvement is prognostic but micro metastases (&lt; 2 mm) does not alter prognosis. Most PTCs are identified in early stages (I or II) with excellent prognosis. Stage IV disease has markedly increased mortality but is rare (~1%).</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">FTC:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> more common in iodine-deficient regions.</span></span></span>\r\n\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Genetics: RAS mutations, PAX8-PPAR&gamma;1 rearrangement.</span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Diagnosis: Difficult by FNA alone, requires Bx to assess capsular/vascular invasion.</span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Prognosis: </span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<ol style=\"list-style-type:lower-alpha; margin-left:80px\">\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Capsular invasion only: Low risk of metastasis, lobectomy suffices. </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Angioinvasive FTC: More aggressive, can metastasize to bone, lung, and CNS.</span></span></span></li>\r\n</ol>\r\n\r\n<ul style=\"list-style-type:circle; margin-left:40px\">\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Higher mortality than PTC, partly due to more frequent stage IV presentation.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Poor Prognostic Factors: Distant metastases, age &gt;55 years, primary tumor size &gt;4 cm, marked vascular invasion.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Lymph node micrometastases (&lt;2 mm) in papillary thyroid carcinoma (PTC) do not alter prognosis, even though lymph node involvement is prognostic.</span></span></span></p>",
      "correct_choice_id": 215442,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53973,
      "choices": [
        {
          "id": 215361,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Thyroid dyshormonogenesis is the most common cause. </span></span></span></p>"
        },
        {
          "id": 215362,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Most infants appear normal at birth. </span></span></span></p>"
        },
        {
          "id": 215363,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">The recommended initial dose of levothyroxine is 10-15 &micro;g/kg/day. </span></span></span></p>"
        },
        {
          "id": 215364,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Early treatment can significantly improve neurodevelopmental outcomes.</span></span></span></p>"
        }
      ],
      "text": "<p><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following statements is false regarding congenital hypothyroidism?</span></span></p>",
      "unique_key": "Q7376021",
      "question_audio": null,
      "question_video": null,
      "map_id": 25567,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Ans. A) Thyroid dyshormonogenesis is the most common cause. </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Most common cause is thyroid gland dysgenesis (65%), followed by Thyroid dyshormonogenesis (30%), and TSH-R antibody mediated (5%). </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Most infants appear normal at birth. Permanent neurologic damage results if treatment is delayed. Cardiac problems are 4x more in congenital hypothyroidism. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option B. Most infants appear normal at birth:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> The majority of infants appear normal at birth (but classic features are prolonged jaundice, poor feeding, hypotonia, macroglossia, delayed bone maturation, and umbilical hernia). </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option C. The recommended initial dose of levothyroxine is 10-15 &micro;g/kg/day:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> When the diagnosis is confirmed, T4 is instituted at a dose of 10&ndash;15 &mu;g/kg/day and the dose is adjusted by close monitoring of TSH levels.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option D. Early treatment can significantly improve neurodevelopmental outcomes:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> Early treatment with T4 results in normal IQ levels, but subtle neurodevelopmental abnormalities may occur in those with the most severe hypothyroidism at diagnosis or when treatment is delayed or suboptimal.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thyroid gland dysgenesis, not thyroid dyshormonogenesis, is the most common cause of congenital hypothyroidism.</span></span></p>",
      "correct_choice_id": 215361,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53987,
      "choices": [
        {
          "id": 215417,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Associated with URI. </span></span></span></p>"
        },
        {
          "id": 215418,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Elevated ESR. </span></span></span></p>"
        },
        {
          "id": 215419,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Positive anti-TPO.</span></span></span></p>"
        },
        {
          "id": 215420,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Giant cells in biopsy.</span></span></span></p>"
        }
      ],
      "text": "<p><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 35-year-old woman presents with a one-week history of fever, neck pain, and fatigue. On physical examination, her thyroid gland is tender. Thyroid function tests reveal elevated free T4 and suppressed TSH. Which of the following statements regarding her underlying condition is FALSE?</span></span></p>",
      "unique_key": "Q8596929",
      "question_audio": null,
      "question_video": null,
      "map_id": 25581,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Ans. C) Positive anti-TPO. </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">The diagnosis is subacute (granulomatous) thyroiditis (a.k.a De Quervain&rsquo;s thyroiditis). </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Disease usually follows an URI and has a classic triphasic course (thyrotoxic </span><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:Wingdings\">&rarr;</span></span><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> hypothyroid </span><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:Wingdings\">&rarr;</span></span><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> resolution). ESR usually elevated and RAIU will be suppressed. TPO antibodies will usually test negative and biopsy typically shows patchy inflammation with granulomas and giant cells. Treatment is supportive (NSAIDs 1st line </span><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:Wingdings\">&rarr;</span></span><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> Prednisolone in case of poor response).</span></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Beta blockers can be used to abate thyrotoxic symptoms and anti-thyroid drugs have NO role. LT4 replacement may be needed if the hypothyroid phase is prolonged, but doses should be low enough (50&ndash;100 &mu;g/d) to allow TSH-mediated recovery. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option </span></strong><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">A. Associated with URI:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> This is a true statement, as De Quervain&rsquo;s thyroiditis is often triggered by a viral infection.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option B. Elevated ESR:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> This is also true due to the inflammatory process.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option D. Giant cells in biopsy:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> This is the characteristic histological finding due to the presence of granulomas in De Quervain&rsquo;s thyroiditis. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Thyroid peroxidase (TPO) antibodies are usually negative in subacute (De Quervain&rsquo;s) thyroiditis, which is associated with an elevated ESR and giant cells in biopsy following an upper respiratory infection.</span></span></span></p>",
      "correct_choice_id": 215419,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53971,
      "choices": [
        {
          "id": 215353,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Graves disease </span></span></span></p>"
        },
        {
          "id": 215354,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Thyrotoxicosis factitia </span></span></span></p>"
        },
        {
          "id": 215355,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Toxic Multinodular Goiter </span></span></span></p>"
        },
        {
          "id": 215356,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Thyroiditis</span></span></span></p>"
        }
      ],
      "text": "<p><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 40-year-old woman presents with a 2-week history of palpitations and excessive sweating. Physical examination reveals a non-tender thyroid gland. Thyroid function tests show an elevated free T4 and suppressed TSH. Radioactive iodine uptake (RAIU) scan is shown. Thyroglobulin levels are low. What is the likely diagnosis?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/17/screenshot-2024-08-17-133042_3j62nY0.jpg\" style=\"height:233px; width:450px\" /></span></span></p>",
      "unique_key": "Q6218190",
      "question_audio": null,
      "question_video": null,
      "map_id": 25565,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Ans. B) Thyrotoxicosis factitia.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">The low RAIU and low thyroglobulin levels in case of thyrotoxicosis confirm that the thyroid gland is not producing excess hormone. Hence, the diagnosis of thyrotoxicosis factitial (exogenous thyroid hormone use).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option A. Graves&#39; disease:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> Graves&#39; disease is an autoimmune condition causing hyperthyroidism. It typically presents with a diffuse goiter, increased RAIU, and high thyroglobulin levels.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option C. Toxic Multinodular Goiter:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> This condition also has an increased RAIU and increased thyroglobulin levels.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option D. Thyroiditis:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> RAIU can be suppressed but thyroglobulin levels are usually elevated in thyroiditis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thyrotoxicosis factitia is characterized by low radioactive iodine uptake (RAIU) and low thyroglobulin levels, indicating exogenous thyroid hormone use.</span></span></p>",
      "correct_choice_id": 215354,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "ImageBased",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53983,
      "choices": [
        {
          "id": 215401,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">RAI therapy is ineffective in young patients. </span></span></span></p>"
        },
        {
          "id": 215402,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">The patient is experiencing a relapse of Graves&#39; disease.</span></span></span></p>"
        },
        {
          "id": 215403,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">The patient is developing hypothyroidism.</span></span></span></p>"
        },
        {
          "id": 215404,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">The full effect of RAI therapy takes 2-3 months to manifest.</span></span></span></p>"
        }
      ],
      "text": "<p><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 25-year-old woman with Graves&#39; disease undergoes RAI therapy. Two months later, she complains of persistent palpitations and heat intolerance. Which of the following is the most likely explanation for her persistent symptoms?</span></span></p>",
      "unique_key": "Q4854169",
      "question_audio": null,
      "question_video": null,
      "map_id": 25577,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Ans. D) The full effect of RAI therapy takes 2-3 months to manifest.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">It can take several weeks to months for RAI to fully destroy thyroid tissue and for symptoms to resolve.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option A</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">. <strong>RAI therapy is ineffective in young patients:</strong> RAI is effective in all age groups.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option B</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">. <strong>The patient is experiencing a relapse of Graves&#39; disease:</strong> Relapse is possible, but less likely within two months.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option C</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">.<strong> The patient is developing hypothyroidism:</strong> &nbsp;Hypothyroidism is a later complication of RAI.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Summary of RAIA in Graves:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Indication</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">: Initial treatment or for relapses after antithyroid drugs.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Tracer used:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> I131. Emits &beta; &amp; &gamma;. t1/2 </span><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Cambria Math&quot;,serif\">&sim;</span></span><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> 8 days. </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Elderly/Cardiac Patients:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> Consider pretreatment with antithyroid drugs and beta-blockers (because of small, increased risk of Thyrotoxic Crisis)</span></span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Carbimazole/Methimazole: Stop 2-3 days before and restart 3-7 days after RAI.</span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">PTU: Prolonged radioprotective effect, requires longer discontinuation or higher RAI dose.</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Persistence of Hyperthyroidism:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> Can persist for 2-3 months, managed with beta-blockers or antithyroid drugs.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Safety Precautions:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> Avoid close contact with children and pregnant women for 5-7 days.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Complications: </span></strong></span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Radiation Thyroiditis: Mild pain may occur 1-2 weeks after treatment.</span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Flare of Orbitopathy: Especially in smokers. Consider prednisone pre-treatment.</span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Permanent Hypothyroidism: Risk is 10-20% in the first year, 5% per year thereafter, requiring lifelong LT4 replacement.</span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Possibly a small increased lifetime risk of solid cancers. </span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Contraindications:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> Pregnancy, breastfeeding and suspected thyroid cancer. </span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The full effect of RAI therapy for Graves&#39; disease takes 2-3 months to manifest, which can explain persistent symptoms shortly after treatment.</span></span></p>",
      "correct_choice_id": 215404,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53979,
      "choices": [
        {
          "id": 215385,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Age &lt; 50 is a risk factor</span></span></span></p>"
        },
        {
          "id": 215386,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Long-term anticoagulation is unnecessary </span></span></span></p>"
        },
        {
          "id": 215387,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Digoxin sensitivity is increased</span></span></span></p>"
        },
        {
          "id": 215388,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Warfarin sensitivity is decreased</span></span></span></p>"
        }
      ],
      "text": "<p><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient with thyrotoxicosis develops atrial fibrillation. Which of the following statements regarding their management is CORRECT?</span></span></p>",
      "unique_key": "Q5503350",
      "question_audio": null,
      "question_video": null,
      "map_id": 25573,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Ans. B) Long-term anticoagulation is unnecessary </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Anticoagulation should be considered in all patients with AF and thyrotoxicosis. There is often spontaneous reversion to sinus rhythm with control of hyperthyroidism, and long-term anticoagulation is not usually required. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Decreased warfarin doses are required when patients are thyrotoxic (sensitivity increased as production of vitamin K dependent clotting factors are reduced).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">If digoxin is used, increased doses are often needed in the thyrotoxic state (sensitivity decreased because of increased renal clearance and increased number of Na-K ATPse)</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option A. Age &lt; 50 is a risk factor:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> Elderly patients (Age &gt;50) are at increased risk.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option C. Digoxin sensitivity is increased:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> Digoxin sensitivity is decreased because of increased renal clearance and increased number of Na-K ATPse.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option D. Warfarin sensitivity is decreased:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> Warfarin sensitivity is increased as production of vitamin K dependent clotting factors are reduced.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Long-term anticoagulation is generally unnecessary in patients with atrial fibrillation and thyrotoxicosis, as spontaneous reversion to sinus rhythm often occurs with control of hyperthyroidism.</span></span></p>",
      "correct_choice_id": 215386,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53969,
      "choices": [
        {
          "id": 215345,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Give Levothyroxine 200&micro;g IV STAT</span></span></span></p>"
        },
        {
          "id": 215346,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Give Hydrocortisone 100mg IV STAT</span></span></span></p>"
        },
        {
          "id": 215347,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Give Levothyroxine 200&micro;g and 100mg Hydrocortisone IV STAT</span></span></span></p>"
        },
        {
          "id": 215348,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Observation and repeat TFT after discharge</span></span></span></p>"
        }
      ],
      "text": "<p><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 68-year-old male presents with congestive heart failure and sepsis. Thyroid function tests (TFT) reveal a low total T3, normal free T4 and normal TSH. What is the next step? </span></span></p>",
      "unique_key": "Q3300920",
      "question_audio": null,
      "question_video": null,
      "map_id": 25563,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Ans. D) Observation and repeat TFT after discharge</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">The patient&#39;s presentation of low total T3, normal free T4, and normal TSH in the setting of congestive heart failure and sepsis is most consistent with <strong>sick euthyroid syndrome (SES)</strong>. SES is a common finding in critically ill patients and is characterized by alterations in thyroid hormone levels without underlying thyroid disease (a.k.a Non Thyroidal Illness)</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">In SES, the conversion of T4 to T3 is often impaired, leading to low T3 levels. However, TSH and free T4 levels are usually normal, as seen in this case.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Management of SES:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> Observation and treat the underlying condition. Can repeat TFTs after recovery from illness if suspicious of underlying thyroid dysfunction. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option A. Give Levothyroxine 200&micro;g IV STAT:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> Levothyroxine replacement is not indicated in SES and may even be harmful.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option B. Give Hydrocortisone 100mg IV STAT:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> This could be appropriate for suspected adrenal insufficiency. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option C. Give Levothyroxine 200&micro;g and 100mg Hydrocortisone IV STAT:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> This could be an appropriate treatment for myxedema coma. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">In patients with sick euthyroid syndrome, characterized by low total T3, normal free T4, and normal TSH in the context of critical illness, observation and repeat TFTs after recovery is the appropriate management.</span></span></span></p>",
      "correct_choice_id": 215348,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53975,
      "choices": [
        {
          "id": 215369,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">A-iv, B-iii, C-ii, D-i</span></span></span></p>"
        },
        {
          "id": 215370,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">A-iv, B-iii, C-i,D-ii</span></span></span></p>"
        },
        {
          "id": 215371,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">A-iii, B-iv, C-i,D-ii</span></span></span></p>"
        },
        {
          "id": 215372,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">A-iii, B-iv, C-ii,D-i</span></span></span></p>"
        }
      ],
      "text": "<p><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Match the following:</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/17/whatsapp-image-2024-08-17-at-121458-pm.jpeg\" style=\"height:246px; width:700px\" /></p>",
      "unique_key": "Q1554300",
      "question_audio": null,
      "question_video": null,
      "map_id": 25569,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) A-iv, B-iii, C-ii, D-i</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">If there is no residual thyroid function, the daily replacement dose of LT4 is usually 1.6 &mu;g/kg body weight (typically 100&ndash;150 &mu;g/d)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Adult patients under 60 years old without evidence of heart disease may be started on 50&ndash;100 &mu;g of LT4 daily.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">For adults with indications to treat in a subclinical hypothyroidism treatment is administered by starting with a low dose of LT4 (25&ndash;50 &mu;g/d).</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In the elderly, especially patients with known coronary artery disease, the starting dose of LT4 is 12.5&ndash;25 &mu;g/d. </span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Standard Adult: 50-100 &micro;g/day</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Post thyroidectomy: 100-150 &micro;g/day</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Coronary Artery Disease: 12.5-25 &micro;g/day</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Subclinical Hypothyroidism: 25-50 &micro;g/day</span></span></span></li>\r\n</ul>",
      "correct_choice_id": 215369,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53977,
      "choices": [
        {
          "id": 215377,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Propranolol</span></span></span></p>"
        },
        {
          "id": 215378,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Propylthiouracil (PTU)</span></span></span></p>"
        },
        {
          "id": 215379,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Radioactive iodine (RAI)</span></span></span></p>"
        },
        {
          "id": 215380,
          "text": "<p><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hydrocortisone</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">A 35-year-old woman with a history of Graves&#39; disease presents to the emergency department with fever, tachycardia, agitation, and vomiting. She recently underwent a dental procedure. Which of the following is the most appropriate initial treatment for her suspected condition?</span></span></span></p>",
      "unique_key": "Q2171098",
      "question_audio": null,
      "question_video": null,
      "map_id": 25571,
      "difficulty_level": "beginner",
      "subjects_id": [],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Ans. B) Propylthiouracil (PTU)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">The patient&#39;s presentation is consistent with thyrotoxic crisis (thyroid storm), a life-threatening complication of hyperthyroidism. PTU is the initial drug of choice due to its rapid onset of action and its ability to inhibit peripheral conversion of T4 to T3.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Mortality of thyroid storm is 30% even with therapy. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option A. Propranolol (A): </span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Can be used for cardio-protection but not immediately required.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option C. Radioactive iodine (C)</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">: Not suitable for acute management of thyrotoxic crisis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option D. Hydrocortisone (D)</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">: Adjunctive therapy in thyroid storm, can be added later.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Propylthiouracil (PTU) is the most appropriate initial treatment for thyrotoxic crisis (thyroid storm) due to its rapid onset of action and ability to inhibit peripheral conversion of T4 to T3.</span></span></span></p>",
      "correct_choice_id": 215378,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53985,
      "choices": [
        {
          "id": 215409,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">TPO and Tg antibodies in the mother can cause fetal hypothyroidism.</span></span></span></p>"
        },
        {
          "id": 215410,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">High Iodine intake increases the risk.</span></span></span></p>"
        },
        {
          "id": 215411,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Thyroid destruction is primarily mediated by the CD8+ cytotoxic T cells.</span></span></span></p>"
        },
        {
          "id": 215412,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Alcohol intake is protective.</span></span></span></p>"
        }
      ],
      "text": "<p><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is false regarding Hashimoto&rsquo;s thyroiditis? </span></span></p>",
      "unique_key": "Q5938502",
      "question_audio": null,
      "question_video": null,
      "map_id": 25579,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Ans. A) TPO and Tg antibodies in the mother can cause fetal hypothyroidism.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Transplacental passage of Tg or TPO antibodies has no effect on the fetal thyroid (but transplacental passage of TSH-R blocking antibodies may induce transient neonatal hypothyroidism). </span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Genetic associations: HLA-DR3/DR4/DR5 &amp; CTLA-4 (weak). Down&rsquo;s and Turner&rsquo;s syndrome patients are at increased risk as well. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option B. High Iodine intake increases the risk: </span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">A high iodine or low selenium intake and decreased exposure to microorganisms in childhood increases risk. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option C. Thyroid destruction is primarily mediated by the CD8+ cytotoxic T cells: </span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">True. Pathogenic effect of antibodies is restricted to a secondary role in amplifying an ongoing autoimmune response.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option D. Alcohol intake is protective:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> Smoking cessation transiently increases incidence, whereas alcohol intake seems protective. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Transplacental passage of Tg or TPO antibodies has no effect on the fetal thyroid, whereas TSH-R blocking antibodies may induce transient neonatal hypothyroidism.</span></span></span></p>",
      "correct_choice_id": 215409,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53994,
      "choices": [
        {
          "id": 215445,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">S. Tg is a sensitive marker post-surgery.</span></span></span></p>"
        },
        {
          "id": 215446,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Universal Target TSH post-surgery is 0.5-2 mIU/L. </span></span></span></p>"
        },
        {
          "id": 215447,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Patient should follow low Iodine diet for 1-2 weeks prior to <sup>I131 </sup>therapy.</span></span></span></p>"
        },
        {
          "id": 215448,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">TSH &gt; 25 is required at the time of I<sup>131</sup> therapy.</span></span></span></p>"
        }
      ],
      "text": "<p><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is false regarding thyroid cancer treatment after thyroidectomy? </span></span></p>",
      "unique_key": "Q7345433",
      "question_audio": null,
      "question_video": null,
      "map_id": 25588,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Ans. B) Universal Target TSH post-surgery is 0.5-2 mIU/L.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Target TSH post-surgery is based on the risk of recurrence. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Low risk of recurrence: 0.5&ndash;2.0 mIU/L</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Intermediate risk of recurrence: 0.1&ndash;0.5 mIU/L</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">High risk of recurrence &amp; metastatic disease: &lt;0.1 mIU/L </span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">I131 therapy:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> Low-iodine diet for 1&ndash;2 weeks before treatment and serum TSH must be &gt;25 mIU/L at the time of therapy (usually achieved by thyroid hormone withdrawal or by rTSH injections). RAIA is not useful if tumour size &lt; 2cm or 2-4 cm + low risk. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option A. S. Tg is a sensitive marker post-surgery:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> This is true. Serum thyroglobulin (Tg) is a useful tumor marker for monitoring patients with papillary and follicular thyroid cancers after thyroidectomy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option C. Patient should follow low Iodine diet for 1-2 weeks prior to I131 therapy:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> This is also true. A low iodine diet is recommended before radioactive iodine (RAI) therapy to enhance the uptake of iodine by any remaining thyroid tissue or cancer cells.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option D. TSH &gt; 25 is required at the time of I131 therapy:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> This is generally true for patients with high-risk thyroid cancer. A higher TSH level helps stimulate the uptake of RAI by thyroid cancer cells.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">The target TSH level post-surgery for thyroid cancer patients is based on the risk of recurrence, not universally 0.5-2 mIU/L. It ranges from 0.5-2.0 mIU/L for low risk, 0.1-0.5 mIU/L for intermediate risk, to &lt;0.1 mIU/L for high risk or metastatic disease.</span></span></span></p>",
      "correct_choice_id": 215446,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53988,
      "choices": [
        {
          "id": 215421,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">De Quervain&#39;s thyroiditis </span></span></span></p>"
        },
        {
          "id": 215422,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Subacute lymphocytic thyroiditis</span></span></span></p>"
        },
        {
          "id": 215423,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Riedel&#39;s thyroiditis</span></span></span></p>"
        },
        {
          "id": 215424,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Hashimoto&#39;s thyroiditis</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">A 30-year-old woman presents to her primary care physician 6 months after delivery with complaints of fatigue, cold intolerance, and weight gain for the last 3 weeks. She also reports feeling depressed and having difficulty concentrating. Her thyroid function tests reveal elevated TSH and low free T4 levels and positive anti-TPO antibodies. Which of the following is the most likely diagnosis?</span></span></span></p>",
      "unique_key": "Q8548669",
      "question_audio": null,
      "question_video": null,
      "map_id": 25582,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Ans. B) Subacute lymphocytic thyroiditis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">The patient&#39;s postpartum presentation with a hypothyroid phase (fatigue, cold intolerance, weight gain, depression, elevated TSH, and low free T4) is characteristic of subacute lymphocytic thyroiditis, also known as painless thyroiditis. The presence of anti-TPO antibodies further supports this diagnosis, as it is an autoimmune condition. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option A. De Quervain&#39;s thyroiditis:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> This is a painful form of thyroiditis and they have an elevated ESR. Anti TPO antibodies are rarely positive in De Quervain&rsquo;s. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option C. Riedel&#39;s thyroiditis:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> This is a rare fibrotic thyroiditis with a hard, fixed goiter.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option D. Hashimoto&#39;s thyroiditis:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> While also autoimmune, Hashimoto&#39;s typically presents with a gradual (chronic) onset of hypothyroidism and is less likely to occur postpartum.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Summary of post-partum thyroiditis:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Similar to De Quervain&rsquo;s thyroiditis, but painless and have normal ESR. </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Occurs in 5% of women 3-6 months postpartum, termed postpartum thyroiditis.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Associated with TPO antibodies antepartum, 3x more common in type 1 diabetes.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Recovery is the rule. Annual follow-up recommended as some develop permanent hypothyroidism. May recur in subsequent pregnancies.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Subacute lymphocytic thyroiditis, also known as painless thyroiditis, often presents postpartum with a hypothyroid phase and positive anti-TPO antibodies.</span></span></p>",
      "correct_choice_id": 215422,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53966,
      "choices": [
        {
          "id": 215333,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Graves&#39; disease</span></span></span></p>"
        },
        {
          "id": 215334,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Toxic multinodular goiter </span></span></span></p>"
        },
        {
          "id": 215335,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Subacute thyroiditis (de Quervain&#39;s thyroiditis) </span></span></span></p>"
        },
        {
          "id": 215336,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">TSH-secreting pituitary adenoma</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">A 35-year-old woman presents with weight loss, heat intolerance, and palpitations. Her TSH is normal, and free T4 is elevated. Which of the following is the most likely cause?</span></span></span></p>",
      "unique_key": "Q3376600",
      "question_audio": null,
      "question_video": null,
      "map_id": 25560,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Ans. D) TSH-secreting pituitary adenoma</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">The combination of normal TSH, elevated free T4 is consistent with central hyperthyroidism. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">TSH-secreting pituitary adenoma is the only cause of central hyperthyroidism in the list, but it is very rare. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option A. Graves&#39; disease:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> TSH would be suppressed as it is a primary hyperthyroidism. RAIU will show diffuse increase in uptake of Iodine. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option B. Toxic multinodular goiter:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> TSH would be suppressed as it is a primary hyperthyroidism. RAIU will show patchy multi-focal increased uptake of Iodine. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option C. Subacute thyroiditis (de Quervain&#39;s thyroiditis):</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> TSH would be suppressed as it is a primary hyperthyroidism. RAIU will show decreased uptake. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">A TSH-secreting pituitary adenoma is indicated by the combination of normal TSH and elevated free T4, consistent with central hyperthyroidism.</span></span></span></p>",
      "correct_choice_id": 215336,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53970,
      "choices": [
        {
          "id": 215349,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Refetoff syndrome</span></span></span></p>"
        },
        {
          "id": 215350,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">TSH-secreting pituitary adenoma </span></span></span></p>"
        },
        {
          "id": 215351,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">McCune-Albright syndrome</span></span></span></p>"
        },
        {
          "id": 215352,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Graves&#39; disease</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">A 4-year-old boy presents with growth retardation, delayed bone age, and normal intellect. His thyroid function tests reveal elevated T3, T4, and normal TSH levels. What is the most likely diagnosis? </span></span></span></p>",
      "unique_key": "Q5748835",
      "question_audio": null,
      "question_video": null,
      "map_id": 25564,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Ans. A) Refetoff syndrome</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Refetoff syndrome, also known as resistance to thyroid hormone (RTH), is a rare genetic disorder. TFTs would show central hyperthyroid picture. There are two types:</span></span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Generalised RTH: Clinically euthyroid/hypothyroid.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Pituitary RTH: Clinically thyrotoxic.</span></span></span></li>\r\n</ul>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">The patient in the vignette is likely to have Generalized RTH. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option B. TSH-secreting pituitary adenoma:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> This would result in elevated TSH and T4 levels, but the patient would likely exhibit symptoms of hyperthyroidism.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option C. McCune-Albright syndrome:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> This syndrome is associated with precocious puberty, bone lesions, and caf&eacute;-au-lait spots.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option D. Graves&#39; disease:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> This autoimmune disorder causes clinical hyperthyroidism with elevated T4 and suppressed TSH levels.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Refetoff syndrome, or resistance to thyroid hormone (RTH), presents with elevated T3 and T4, normal TSH levels, growth retardation, and delayed bone age, with the patient usually being clinically euthyroid or hypothyroid.</span></span></p>",
      "correct_choice_id": 215349,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53972,
      "choices": [
        {
          "id": 215357,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Alopecia </span></span></span></p>"
        },
        {
          "id": 215358,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Amenorrhea </span></span></span></p>"
        },
        {
          "id": 215359,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Carpal tunnel syndrome </span></span></span></p>"
        },
        {
          "id": 215360,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Cardiac tamponade</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">A 34-year-old woman presents with a 3-month history of fatigue and constipation. Thyroid function tests show reduced free T4 and increased TSH levels. Which of the following symptoms or signs is LEAST likely to be associated with her condition?</span></span></span></p>",
      "unique_key": "Q1533493",
      "question_audio": null,
      "question_video": null,
      "map_id": 25566,
      "difficulty_level": "beginner",
      "subjects_id": [],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Ans. D) Cardiac tamponade</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">The clinical presentation and lab results are consistent with primary hypothyroidism. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Pericardial effusion occurs in 30% patients but cardiac tamponade is an unlikely event. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option A. Alopecia:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> Hypothyroidism can cause hair loss due to slowed metabolism and decreased hair growth.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option B. Amenorrhea:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> Hypothyroidism can disrupt menstrual cycles (Menorrhagia initially and oligo/amenorrhea in long standing disease).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option C. Carpal tunnel syndrome:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> Hypothyroidism can cause fluid retention and swelling, which can compress the median nerve in the wrist, leading to carpal tunnel syndrome</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cardiac tamponade is the least likely symptom associated with primary hypothyroidism, despite pericardial effusion being relatively common.</span></span></p>\r\n\r\n<p>&nbsp;</p>",
      "correct_choice_id": 215360,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53974,
      "choices": [
        {
          "id": 215365,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Ask her to review immediately to the hospital </span></span></span></p>"
        },
        {
          "id": 215366,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Ask her to take 2 tablets today </span></span></span></p>"
        },
        {
          "id": 215367,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Skip the missed dose and resume from today </span></span></span></p>"
        },
        {
          "id": 215368,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Ask her to take TFT and review </span></span></span></p>"
        }
      ],
      "text": "<p><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old hypothyroid patient calls your OPD and informs that she has missed her thyroxine tablet the previous day and asks what to do about it. What will be your advice?</span></span></p>",
      "unique_key": "Q7031415",
      "question_audio": null,
      "question_video": null,
      "map_id": 25568,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Ans. B) Ask her to take 2 tablets today </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Because T4 has a long half-life (7 days), patients who miss a dose can be advised to take two doses of the skipped tablets at once. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">All others are incorrect by default. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Advise hypothyroid patients who miss a dose of thyroxine to take two doses the next day due to the long half-life of T4.</span></span></span></p>",
      "correct_choice_id": 215366,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53976,
      "choices": [
        {
          "id": 215373,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Levothyroxine 200</span><span style=\"font-size:12.0pt\"> &mu;g IV bolus</span></span></span></p>"
        },
        {
          "id": 215374,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">IV Hydrocortisone 50mg 6<sup>th</sup> hourly</span></span></span></p>"
        },
        {
          "id": 215375,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">IV broad spectrum Antibiotics</span></span></span></p>"
        },
        {
          "id": 215376,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">External Rewarming</span></span></span></p>"
        }
      ],
      "text": "<p><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 65-year-old woman with a history of Hashimoto&#39;s thyroiditis is brought to the emergency department with altered mental status, hypothermia (35&deg;C), bradycardia (45 bpm), and hypotension (80/50 mmHg). Her skin is dry and doughy, and she has non-pitting edema in her extremities. Which of the following is the NOT indicated?</span></span></p>",
      "unique_key": "Q3469208",
      "question_audio": null,
      "question_video": null,
      "map_id": 25570,
      "difficulty_level": "beginner",
      "subjects_id": [],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) External Rewarming</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Blankets (passive warming) can be used to prevent heat loss in myxedema coma but external (active) warming is indicated only if the temperature is &lt;30&deg;C, as it can result in cardiovascular collapse. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mortality in myxedema coma is 20-40% despite appropriate treatment. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.&nbsp;</span></strong><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Levothyroxine 200</span></strong><strong><span style=\"font-size:12.0pt\"> &mu;g IV bolus:</span></strong><span style=\"font-size:12.0pt\"> LT4 single IV bolus of 200&ndash;400 &mu;g (loading dose) is the preferred initial treatment in myxedema coma (alternate if no IV avaialble: NG tube LT4).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. IV Hydrocortisone 50mg 6<sup>th</sup> hourly:</span></strong><span style=\"font-size:12.0pt\"> Parenteral hydrocortisone (50 mg every 6 h) should be administered because there is impaired adrenal reserve in profound hypothyroidism</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. IV broad spectrum Antibiotics:</span></strong><span style=\"font-size:12.0pt\"> Sepsis is an important precipitating cause of myxedema coma. Early use of broad-spectrum antibiotics is warranted until infection is excluded.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">External (active) rewarming is not indicated for myxedema coma unless the temperature is below 30&deg;C, as it can result in cardiovascular collapse.</span></span></span></p>",
      "correct_choice_id": 215376,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53978,
      "choices": [
        {
          "id": 215381,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Sinus Tachycardia</span></span></span></p>"
        },
        {
          "id": 215382,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Polyuria</span></span></span></p>"
        },
        {
          "id": 215383,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Hypercalcemia</span></span></span></p>"
        },
        {
          "id": 215384,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypocalciuria</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All of the following are features of thyrotoxicosis except:</span></span></p>",
      "unique_key": "Q5816425",
      "question_audio": null,
      "question_video": null,
      "map_id": 25572,
      "difficulty_level": "beginner",
      "subjects_id": [],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Hypocalciuria</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Hypercalciuria is common in thyrotoxicosis (may be because of underlying hypercalcemia which is seen in 20% cases). This is due to direct effect of thyroid hormones on bone resorption (which can lead to osteopenia in longstanding thyrotoxicosis). </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option A. Sinus Tachycardia: </span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">The most common CV manifestation in thyrotoxicosis is sinus tachycardia.&nbsp; Atrial fibrillation is more common in patients &gt;50 years of age.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option B. Polyuria</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">: Probably due to increased renal blood flow and hypercalciuria.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option C. Hypercalcemia: </span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">This is due to the effect of thyroid hormones causing bone resorption.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypercalciuria, not hypocalciuria, is a common feature of thyrotoxicosis due to the effect of thyroid hormones on bone resorption.</span></span></p>",
      "correct_choice_id": 215384,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53980,
      "choices": [
        {
          "id": 215389,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">MRI of the orbit </span></span></span></p>"
        },
        {
          "id": 215390,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">X-ray of hands with wrist </span></span></span></p>"
        },
        {
          "id": 215391,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">CT of the chest </span></span></span></p>"
        },
        {
          "id": 215392,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Repeat TFT</span></span></span></p>"
        }
      ],
      "text": "<p><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 54-year-old male smoker with a history of Graves&#39; disease presents with weight loss and loss of appetite. He is on carbimazole 5mg per day, and his recent free T4 levels (done a week ago) were normal. He has mild orbitopathy but no dermopathy. On examination, you notice clubbing; otherwise, he is vitally stable. What is the next step?</span></span></p>",
      "unique_key": "Q9538479",
      "question_audio": null,
      "question_video": null,
      "map_id": 25574,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Ans. C) CT of the chest</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">The presence of clubbing in a smoker, especially with new-onset weight loss and loss of appetite, raises a high suspicion of underlying lung malignancy. Even though his thyroid function tests were normal a week ago, the concerning finding of clubbing necessitates further investigation to rule out a serious underlying condition.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option A. MRI of the orbit:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> It not the primary concern given the new symptoms and clubbing.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option B. X-ray of hands with wrist:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> May be useful in thyroid acropachy (It refers to a form of clubbing found in &lt; 1% of patients with Graves&rsquo; disease. It is so strongly associated with thyroid dermopathy that an alternative cause of clubbing should be sought in a Graves&rsquo; patient without coincident skin and orbital involvement).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option D. Repeat TFT:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> Repeating thyroid function tests is unlikely to yield new information. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">In a smoker with Graves&#39; disease presenting with clubbing, weight loss, and loss of appetite, a CT of the chest is indicated to rule out an underlying lung malignancy.</span></span></span></p>",
      "correct_choice_id": 215391,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53982,
      "choices": [
        {
          "id": 215397,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Poor intrauterine growth</span></span></span></p>"
        },
        {
          "id": 215398,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Fetal tachycardia </span></span></span></p>"
        },
        {
          "id": 215399,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Reduced Bone Age</span></span></span></p>"
        },
        {
          "id": 215400,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Fetal goiter</span></span></span></p>"
        }
      ],
      "text": "<p><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is unlikely in a case of neonatal thyrotoxicosis?</span></span></p>",
      "unique_key": "Q8895439",
      "question_audio": null,
      "question_video": null,
      "map_id": 25576,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Ans. C) Reduced Bone Age</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Transplacental transfer of antibodies (from mother with Graves) can cause fetal or neonatal thyrotoxicosis. Features include Poor intrauterine growth, a fetal heart rate of &gt;160 beats/min, advanced (not reduced) bone age, fetal goiter. Risk increases substantially if the antibody levels (especially &ge; 26 weeks) are 3x higher than the normal range. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option A. Poor intrauterine growth:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> Common feature due to increased basal metabolic rate in the fetus with thyrotoxicosis. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option C. Fetal tachycardia:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> HR &gt; 160/min is commin in the fetus with thyrotoxicosis. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option D. Fetal goiter:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> Common due to trophic effects of antibodies on the thyroid gland.&nbsp; </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Neonatal thyrotoxicosis is associated with advanced bone age, not reduced bone age.</span></span></span></p>",
      "correct_choice_id": 215399,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53984,
      "choices": [
        {
          "id": 215405,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Multiple sclerosis </span></span></span></p>"
        },
        {
          "id": 215406,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Progressive multifocal leukoencephalopathy (PML) </span></span></span></p>"
        },
        {
          "id": 215407,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Hashimoto&#39;s encephalopathy </span></span></span></p>"
        },
        {
          "id": 215408,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Neurosarcoidosis</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">A 55-year-old woman presents with progressive confusion, memory loss, and seizures. She also has a history of hypothyroidism and she is on Levothyroxine 75 &micro;g/d. Her records suggest a high anti TPO antibodies and MRI of the brain reveals diffuse white matter hyperintensities. Which of the following is the most likely diagnosis?</span></span></span></p>",
      "unique_key": "Q5198141",
      "question_audio": null,
      "question_video": null,
      "map_id": 25578,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Ans. C) Hashimoto&#39;s encephalopathy</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Hashimoto&#39;s encephalopathy (HE), also known as steroid-responsive encephalopathy associated with autoimmune thyroiditis (SREAT), fits this clinical picture. The patient&#39;s history of Hashimoto&#39;s thyroiditis, along with the cognitive decline, seizures, and white matter changes on MRI, strongly suggest HE.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option A. Multiple sclerosis (MS):</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> MS follows dissemination in space and time and it is not associated with anti TPO antibodies. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option B. Progressive multifocal leukoencephalopathy (PML): </span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">It is caused by JC virus and is usually seen in immunocompromised individuals. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option D. Neurosarcoidosis:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> The clinical features are NOT compatible with the diagnosis. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Hashimoto&#39;s encephalopathy, also known as steroid-responsive encephalopathy associated with autoimmune thyroiditis (SREAT), is characterized by progressive confusion, memory loss, seizures, high anti-TPO antibodies, and diffuse white matter hyperintensities on MRI.</span></span></span></p>",
      "correct_choice_id": 215407,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53986,
      "choices": [
        {
          "id": 215413,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Lymphocytic infiltration </span></span></span></p>"
        },
        {
          "id": 215414,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Atrophy of thyroid follicles </span></span></span></p>"
        },
        {
          "id": 215415,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Absence of fibrosis </span></span></span></p>"
        },
        {
          "id": 215416,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Goiter</span></span></span></p>"
        }
      ],
      "text": "<p><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 24-year-old woman presents with severe fatigue. Thyroid function tests reveal low free T4, high TSH, and elevated anti-TPO antibodies. Which of the following statements regarding the histopathological findings in her thyroid gland is FALSE?</span></span></p>",
      "unique_key": "Q6614914",
      "question_audio": null,
      "question_video": null,
      "map_id": 25580,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Ans. C) Absence of fibrosis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">The patient&#39;s clinical presentation and laboratory results are consistent with Hashimoto&#39;s thyroiditis. Histopathological findings are lymphocytic infiltration (can form germinal centres), atrophy of thyroid follicles and fibrosis. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option A. Lymphocytic infiltration:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> Hallmark of Hashimoto&rsquo;s thyroiditis and can form germinal centres within the gland. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option B. Atrophy of thyroid follicles:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> The destruction of thyroid follicles by the immune system leads to their shrinkage and atrophy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option D. Goiter:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> In the early stages of Hashimoto&#39;s, the thyroid gland may become enlarged (goiter) due to inflammation. However, as the disease progresses, the gland can shrink due to atrophy. Atrophy is especially common in Asians. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Hashimoto&#39;s thyroiditis histopathology includes lymphocytic infiltration, atrophy of thyroid follicles, and fibrosis.</span></span></span></p>",
      "correct_choice_id": 215415,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53989,
      "choices": [
        {
          "id": 215425,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Start treatment with levothyroxine</span></span></span></p>"
        },
        {
          "id": 215426,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Initiate radioactive iodine therapy</span></span></span></p>"
        },
        {
          "id": 215427,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Perform open biopsy for definitive diagnosis</span></span></span></p>"
        },
        {
          "id": 215428,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Begin glucocorticoid therapy</span></span></span></p>"
        }
      ],
      "text": "<p><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 40-year-old woman presents with a firm, non-tender, fixed goiter and complaints of difficulty swallowing and hoarseness. Fine needle aspiration is inconclusive. Which of the following is the most appropriate next step in the management of this patient?</span></span></p>",
      "unique_key": "Q1456920",
      "question_audio": null,
      "question_video": null,
      "map_id": 25583,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Ans. C) Perform open biopsy for definitive diagnosis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">The patient&#39;s clinical presentation of a firm, painless, fixed goiter with compressive symptoms (dysphagia, hoarseness) is highly suggestive of Riedel&#39;s thyroiditis. An open biopsy is necessary to confirm the diagnosis and rule out malignancy, which can present with similar features. FNA is often inconclusive in Riedel&rsquo;s thyroiditis. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">There is an association between Riedel&rsquo;s thyroiditis and IgG4-related disease causing idiopathic fibrosis at other sites (retroperitoneum, mediastinum, biliary tree, lung, and orbit).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option A. Start treatment with levothyroxine:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> Levothyroxine is used to treat hypothyroidism, which is uncommon (TFT is often normal) in Riedel&#39;s thyroiditis. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option B. Initiate radioactive iodine therapy:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> Radioactive iodine therapy is used to treat hyperthyroidism, not indicated in this case.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option D. Begin glucocorticoid therapy:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> Glucocorticoids may be considered after a definitive diagnosis of Riedel&#39;s thyroiditis is established, but not as the initial step.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Perform an open biopsy for a definitive diagnosis in a patient with a firm, non-tender, fixed goiter and compressive symptoms, as this presentation is highly suggestive of Riedel&#39;s thyroiditis.</span></span></span></p>",
      "correct_choice_id": 215427,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53990,
      "choices": [
        {
          "id": 215429,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Potassium perchlorate </span></span></span></p>"
        },
        {
          "id": 215430,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">High-dose antithyroid drugs </span></span></span></p>"
        },
        {
          "id": 215431,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Glucocorticoids (prednisone)</span></span></span></p>"
        },
        {
          "id": 215432,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Thyroidectomy</span></span></span></p>"
        }
      ],
      "text": "<p><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 65-year-old man with a history of atrial fibrillation treated with amiodarone presents with weight loss, palpitations, and heat intolerance. Thyroid function tests reveal suppressed TSH and elevated free T4. Thyroid USG shows decreased vascularity. What is the most appropriate management?</span></span></p>",
      "unique_key": "Q3246424",
      "question_audio": null,
      "question_video": null,
      "map_id": 25584,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Ans. C) Glucocorticoids (prednisone)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">The patient has amiodarone-induced thyrotoxicosis (AIT) type 2, characterized by destructive thyroiditis (decreased vascularity on ultrasound). Glucocorticoids are the first-line treatment for this type.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option A. Potassium perchlorate:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> Used in type 1 AIT (increases synthesis, increased vascularity).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option B. High-dose antithyroid drugs:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> Also used in type 1 AIT, ineffective in type 2 due to the release of preformed hormone.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option D. Thyroidectomy:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> Reserved for severe, unresponsive cases, not the initial approach.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Glucocorticoids (prednisone) are the first-line treatment for amiodarone-induced thyrotoxicosis (AIT) type 2, characterized by destructive thyroiditis and decreased vascularity on ultrasound.</span></span></span></p>",
      "correct_choice_id": 215431,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53992,
      "choices": [
        {
          "id": 215437,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Male gender </span></span></span></p>"
        },
        {
          "id": 215438,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Age &gt; 65 years </span></span></span></p>"
        },
        {
          "id": 215439,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Papillary histology </span></span></span></p>"
        },
        {
          "id": 215440,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">p53 mutations</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">A 72-year-old male presents with a rapidly enlarging neck mass and hoarseness. Fine needle aspiration biopsy reveals thyroid cancer. Which of the following factors is NOT associated with a poor prognosis in this patient?</span></span></span></p>",
      "unique_key": "Q5378563",
      "question_audio": null,
      "question_video": null,
      "map_id": 25586,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Ans. C) Papillary histology</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Papillary thyroid cancer is the most common type of thyroid cancer and generally has a good prognosis, even in older patients. The presence of papillary histology would NOT be associated with a poor prognosis in this scenario.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option A. Male gender:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> Male gender is associated with a worse prognosis in thyroid cancer compared to female gender.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option B. Age &gt; 65 years:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> Older age at diagnosis is a significant risk factor for poorer outcomes in thyroid cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option D. p53 mutations:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> p53 mutations are associated with a more aggressive tumor behavior and a poorer prognosis in thyroid cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Papillary histology in thyroid cancer is not associated with a poor prognosis and generally indicates a good outcome.</span></span></span></p>",
      "correct_choice_id": 215439,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}